Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 5th 2015

AbbVie to Buy Oncology Company Pharmacyclis

AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.

March 4th 2015

Nivolumab Approved for NSCLC

The FDA announced today that it has approved Opdivo (nivolumab) for use in NSCLC patients who have progressed on or after platinum-based chemotherapy.

March 4th 2015

Brain Tumor Patients Fare Poorly if Uninsured or on Medicaid, Study Reports

Brain tumor patients who are uninsured or use Medicaid stay hospitalized longer and develop more medical complications than those with private insurance, University of Florida Health researchers have found.

March 4th 2015

Multibillion Spent on Drug Development, But Is It Helping?

While the pharmaceutical industry has always justified the billions spent on developing a candidate drug molecule, the process has definitely seen some important changes. This article evaluates whether these revolutionary changes have influenced drug development for the better.

March 3rd 2015

Imaging Study Identifies Pre-Cancerous Changes in Breast Tissue

The technique, L-COSY, monitors biochemical changes in tissue and could improve the management of women at risk of breast cancer, such as those carrying mutations in BRCA1 and BRCA2.

March 3rd 2015

Study Evaluates Cost-Benefit of US Spending on Cancer Care

The study in Health Affairs published by Samir Soneji, PhD, an assistant professor at Dartmouth's Geisel School of Medicine and The Dartmouth Institute for Health Policy & Clinical Practice, found that despite a sharp rise in healthcare spending,caner mortality rates are very high in the US compared to Western Europe.

March 3rd 2015

Study Findings Validate the Use of Adjuvant Systemic Therapy in Gastrointestinal Tumors

The use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time, a new study published in the American Journal of Clinical Oncology, has found, and patients treated with the therapy have better survival than those treated with surgery alone, researchers say.

March 3rd 2015

Novation Survey Underscores Problems With Genetech's Specialty Drug Distribution Changes

The study found that following Genetech's decision to restrict the distribution of it's 3 popular cancer medications through specific specialty distributors, patient access to the drugs has reduced while costs have increased.

March 2nd 2015

Kyprolis Trumps Velcade in Multiple Myeloma Trial

Results released by Amgen, who bought the molecule from Onyx, show that Kyprolis yielded better results when used as second-line in relapsed patients.

March 2nd 2015

Web-Based Tool Designed to Improve Quality of Care in Thyroid Cancer

The Thyroid Cancer Clinical Registry is expected to improve quality of patient care as patient data would be readily available to all physicians involved in the patients care; however former Commission on Cancer chair Frederick L Greene, MD, wonders whether physicians would take the time to enter the clinical data into the system as required.

February 28th 2015

Urine Test for Bladder Cancer Could Aid Early Detection

A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.

February 27th 2015

Opdivo Gets Priority Review for NSCLC

BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.

February 27th 2015

Studies Highlight Limitations in Emergency Provider Understanding of End-of-Life Care Choices

Emergency care providers vary in their understanding of a type of medical order intended to communicate seriously ill patients' choices for life-sustaining treatments, according to a pair of studies recently published.

February 27th 2015

AJMC Panel Sees Advantages in FDA Regulation of Molecular Diagnostic Tests for Cancer Care

The American Journal of Managed Care convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA's plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.

February 27th 2015

Community Oncology Alliance Announces Launch of Accreditation Pilot for OMH

Ten oncology practices around the nation will initiate their accreditation process this year, which includes an on-site survey bu the Commission on Cancer.

February 26th 2015

NICE Guidelines for Bladder Cancer Can Minimize Care Variance

NICE's first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

February 26th 2015

Dr Ira Klein Discusses the CMS Oncology Care Model

The goals of the new CMS Oncology Care Model align very nicely with what payers want, according to Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer, Aetna.

February 26th 2015

Basket Trials Have FDA Support, But Will They Deliver?

Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.

February 25th 2015

Fred Hutch Receives Multimillion Dollar Cancer Research Grant from PCORI

Project to research better way to treat neutropenia is 1 of 5 to get latest funding from Patient-Centered Outcomes Research Institute.

February 25th 2015

NICE Rejects Provenge, Says Treatment is Not Cost-Effective

The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.

February 24th 2015

Shared Decision-Making in Cancer Has Several Variables

A study published in the journal Cancer provides insights that may help physicians understand patients' preferences regarding their care, which may be crucial for optimizing patient participation in treatment decisions.

February 24th 2015

Study Results Could Improve Quality of Life in Pediatric ALL

The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.

February 24th 2015

Study Warns Against Use of VEGF Inhibitors in Advanced Kidney Cancer

Interim analysis of a clinical trial evaluating adjuvant sorafenib, sunitinib or placebo in patients with advanced renal cell carcinoma found the recurrence rates and the disease-free survival were similar between all three treatment regimens.

February 23rd 2015

First HDAC Inhibitor, Developed by Novartis, Approved for Multiple Myeloma

Study results showed participants receiving Farydak with bortezomib and dexamethasone saw a progression-free survival for about 10.6 months,compared to 5.8 months in participants treated with bortezomib and dexamethasone alone.

February 23rd 2015

Coalition of Leading Cancer Centers Aims to Improve Personalized Treatment

"The growth of ORIEN coincides with President Obama's announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer," said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.

February 23rd 2015

BMS Deals Set to Boost Company's Oncology Pipeline

The deals, with Flexus and Rigel, will add another molecule to the company's immunotherapy pipeline and also provide access to a TGF-beta receptor inhibitor to be used in combination with Yervoy and Opdivo.

February 23rd 2015

Taiho's NDA for mCRC Under FDA Review

The TAS-102 RECOURSE trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo, and the results of the trial form the basis of the NDA.

February 23rd 2015

Expert Analysis on Managing mCRC

At the 26th International Congress on Anti-Cancer Treatment in Paris, France, earlier this month, oncologists deliberated on the current understanding of metastatic colorectal cancer and the available treatment options. Recent work has shown that there are 4 or 5 different subtypes of the disease, which may call for personalized therapeutic strategies.

February 21st 2015

Managed Care Minute: February 21, 2015

A one-minute look at managed care news during the week of February 16, 2015, including extended open enrollment under the Affordable Care Act and shared decision-making for cancer treatments.

February 20th 2015

Celgene's Revlimid Receives Expanded Approval in Europe Following Similar FDA Approval

After the FDA approved lenalidomide for use in chemotherapy-naive multiple myeloma (MM) patients, the European Commission has followed suit. Revlimid was approved today by EC in MM patients, previously untreated and transplant-ineligible.

...

135 136 137 138 139 140 141 142 143

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions